Protective immunity induced by rPb27 of Paracoccidioides brasiliensis

Reis, Bernardo Sgarbi; Fernandes, Viviane Cristina; Martins, Estefânia M.N.; Serákides, Rogéria; Góes, Alfredo M.

doi:10.1016/j.vaccine.2008.07.097

Cited by 37 publications

(35 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result is understandable because unlike Mexo, rPb27 is a much more specific molecule, which limits the epitopes recognised by IgG. Reis et al (2008) immunised mice with the antigenic rPb27 fraction and measured their humoral immunological response. These mice produced high levels of IgG2b, moderate levels of IgG1 and low levels of IgG2a.…”

Section: Discussionmentioning

confidence: 97%

“…The sequence of the recombinant rPb27 had already been cloned by our group into the expression vector pGEX 4T-2 (Gibco BRL) (GST), as described by Reis et al (2008). To facilitate the purification procedure, the rPb27 sequence was transferred, according to the manufacturer's instructions, into the expression vector pET-DEST 42 (Invitrogen, Carlsbad, USA), which allowed for the expression of the recombinant protein with a C-terminal his-tag.…”

Section: Subjects Materials and Methodsmentioning

confidence: 99%

“…These techniques may use various antigenic preparations to assess antibodies against P. brasiliensis. Some of these techniques use crude antigenic preparations, while others use specific antigenic preparations, such as the 19 kDa, 31 kDa, 43 kDa and 70 kDa glycoproteins and recombinant Pb27 (rPb27) (Ortiz et al 1998, Baida et al 1999, Díez et al 2003, Albuquerque et al 2005, Correa et al 2007, Reis et al 2008, Fernandes et al 2011, Silveira-Gomes et al 2011. However, there is no consensus on the best techniques for the diagnosis and follow-up care of PCM patients (Campos et al 1990, Alves 1996, Martins et al 1997, Del Negro et al 2000, Camargo 2008).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Profile of total IgG, IgG1, IgG2, IgG3 and IgG4 levels in sera of patients with paracoccidioidomycosis: treatment follow-up using Mexo and rPb27 as antigens in an ELISA

Santos

Fernandes

Cruz

et al. 2012

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Subjects Materials and Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Profile of total IgG, IgG1, IgG2, IgG3 and IgG4 levels in sera of patients with paracoccidioidomycosis: treatment follow-up using Mexo and rPb27 as antigens in an ELISA

Santos

Fernandes

Cruz

et al. 2012

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…Other specific proteins of P. brasiliensis used to standardize diagnostic tests are gp70 and gp87 and the recombinant 27-kd, rPb27 [Ortiz et al, 1998;Diez et al, 2002Diez et al, , 2003Marques da Silva et al, 2003;da Silva et al, 2004;Camargo, 2008]. Some studies have demonstrated the applicability of the antigens gp43 and rPb27 in the development of a prophylactic vaccine against PCM [Braga et al, 2009;Pinto et al, 2000;Reis et al, 2008;Travassos et al, 2008a].…”

Section: Diagnosis Of Pcmmentioning

confidence: 99%

Fundamentals of paracoccidioidomycosis treatment

Fróes

Caligiorne

2011

Drug Development Research

View full text Add to dashboard Cite

Paracoccidioidomycosis (PCM) is the most important mycosis in Latin America. The etiological agent is the fungus, Paracoccidioides brasiliensis. Approximately 1 million people are infected with the fungus, 10% of whom will show symptoms of the disease. However, clinical and laboratorial studies addressing the diagnosis for this disease are both scarce and diverse in terms of definition. Nevertheless, two main advances were included in the portfolio of available diagnostic methods for paracoccidioidomycosis during the last decades: the detection of antibodies against P. brasiliensis antigens by serological methods, and the detection of the fungi DNA in peripheral blood and fragments of lesions using the polymerase chain reaction (PCR) assay and species-specific primers. Normally, the treatment of PCM is quite prolonged because of the immunosuppressed profile of the patients and the ability of P. brasiliensis to survive in the tissues even after long-term treatment. Case reports indicate that azoles and sulfa compounds can produce positive results in less severe cases of PCM. However, for acute cases of the disease in immunocompromised patients or in cases of neuroparacoccidioidomycosis, there is no standard treatment. Thus, there is a need to establish a standard treatment protocol within the context of the patient clinical profile. Moreover, drug availability to public institutions is an important issue, since new drugs, e.g., second-generation azoles, the echinocandines and immunomodulatory drugs, are not yet available in public hospitals and clinics. Drug Dev Res 72:528-537, 2011.

show abstract

“…In addition, it has been shown to promote protective immunity in BALB/c mice against infection with P. brasiliensis yeast forms (Fernandes et al, 2011b;Reis et al, 2008), enhancing the PCM antifungal therapy (Fernandes et al, 2011b), and has been suggested as a putative virulence factor (Matute et al, 2008;Ortiz et al, 1996;Reis et al, 2008). Nonetheless, the function of this protein remains unknown.…”

Section: Introductionmentioning

confidence: 99%